Clinical Investigations in Boron Neutron Capture Therapy (BNCT): Pharmacokinetic, Biodistribution, and Toxicity of Na2B12H11SH (BSH) in Patients with Malignant Glioma

One of the goals of the European Collaboration on Boron Neutron Capture Therapy is to treat malignant gliomas (WHO grade III–IV), using Na2B12H11SH (BSH) as boron carrier. To treat these tumors with boron neutron capture therapy, it is necessary to accumulate sufficient amounts of boron in the tumor prior to irradiation and at the same time ensure that healthy tissue unavoidably present in the neutron beam contains a minimal amount of boron.